Given the fact that Dr. Chan has received our prod

Quote:

---

Given the fact that Dr. Chan has received our product and We All wish him the best...pinning hopes on one patient has Never really helped our case.

---

The problem with right to try/compassionate use is leronlimab is usually used as a last option when patients are in dire straits due to all other approved options needing to be exhausted. By then large amounts of damage is already done and leronlimab has to try and recover patients from that. If it could be used earlier in treatment that damage wouldn't exist.

The same goes for trials that have numerous existing effective and approved drugs. We're stuck as third or fourth line treatment when using leronlimab from the start would have much greater benefit. With MASH, ME/CFS and Alzheimer's we won't have that problem.